UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008756
Receipt number R000010285
Scientific Title Abatacept-based approach to cure of RA
Date of disclosure of the study information 2012/08/30
Last modified on 2012/08/23 15:27:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Abatacept-based approach to cure of RA

Acronym

ACURE study

Scientific Title

Abatacept-based approach to cure of RA

Scientific Title:Acronym

ACURE study

Region

Japan


Condition

Condition

Rheumatoid Arthritis

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the possibility of biologic free of abatacept

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Proportion of patients with remission at month 24

Key secondary outcomes

1, RF, anti CCP antibody at month 24
2, delta TSS at month 24
3. HAQ at month 24
4, DAS 28 at month 30
5, RF, anti CCP antibody at month 30
6, delta TSS at month 30
7, HAQ at month 30


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Abatacept treatmentat month 12

Interventions/Control_2

MTX treatment at month 12

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1.RA patients
2.Treated with MTX more than 6mg/week and biologic agents other than abatacept, DAS28-ESR less than 3.2
3.Patients with drug free wish
4.Consent about non-randomization
5.Patients who give a full consent to this study

Key exclusion criteria

1,Contraindication with abatacept
2, Patients treated with abatacept
3, Using PSL, plasma pheresis, joint replacement and other surgical treatment
4 Chronic active EBV infection
5,Chronic HBV infection
6, Infection
7, Patients who are pregnant, who are nursing or who hope to be pregnant
8, Patients who are inadequate by investigator's decision.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshiya Tanaka

Organization

University of Occupational and Environmental Health, Japan

Division name

The First Department of Internal Medicine, School of Medicine

Zip code


Address

1-1, Iseigaoka, Yahatanishi, Kitakyushu, Japan

TEL

0936031611

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yoshiya Tanaka

Organization

University of Occupational and Environmental Health, Japan

Division name

The First Department of Internal Medicine, School of Medicine

Zip code


Address

1-1, Iseigaoka, Yahatanishi, Kitakyushu, Japan

TEL

0936031611

Homepage URL


Email



Sponsor or person

Institute

University of Occupational and Environmental Health, Japan

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 08 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2010 Year 09 Month 30 Day

Date of IRB


Anticipated trial start date

2010 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 08 Month 23 Day

Last modified on

2012 Year 08 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010285


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name